List of Excipients in Branded Drug TOPCARE ALL NIGHT PAIN RELIEF PM

« Back to Dashboard

Generic Drugs Containing TOPCARE ALL NIGHT PAIN RELIEF PM

Company	Ingredient	NDC	Excipient
Topco Associates LLC	diphenhydramine hydrochloride, naproxen sodium	36800-264	CELLULOSE, MICROCRYSTALLINE
Topco Associates LLC	diphenhydramine hydrochloride, naproxen sodium	36800-264	CROSCARMELLOSE SODIUM
Topco Associates LLC	diphenhydramine hydrochloride, naproxen sodium	36800-264	FD&C BLUE NO. 1 ALUMINUM LAKE
Topco Associates LLC	diphenhydramine hydrochloride, naproxen sodium	36800-264	FD&C BLUE NO. 2 ALUMINUM LAKE

What are the Most Frequently-Used Excipients in TOPCARE ALL NIGHT PAIN RELIEF PM?

# Of NDCs	Excipient
1	CELLULOSE, MICROCRYSTALLINE
1	CROSCARMELLOSE SODIUM
1	FD&C BLUE NO. 1 ALUMINUM LAKE
1	FD&C BLUE NO. 2 ALUMINUM LAKE

Last updated: August 23, 2026

Executive summary: TOPCARE All Night Pain Relief PM is a private-label nighttime analgesic combining acetaminophen 500 mg with doxylamine succinate 25 mg per caplet. Its commercial value comes from formulation execution, retail distribution, compliance, and line extensions rather than patent exclusivity. The strongest excipient opportunities are low-cost direct compression, rapid dissolution, improved caplet swallowability, moisture control, color and coating optimization, and differentiated delivery formats that remain within FDA OTC requirements.

TOPCARE All Night Pain Relief PM Excipient Strategy and Commercial Opportunities

What is TOPCARE All Night Pain Relief PM?

TOPCARE All Night Pain Relief PM is an over-the-counter nighttime pain-relief product. Its active ingredients are generally listed as:

Component	Strength per caplet	Function
Acetaminophen	500 mg	Analgesic and fever reducer
Doxylamine succinate	25 mg	Nighttime sleep aid

The product is positioned against Tylenol PM and other store-brand acetaminophen-doxylamine products. The formulation addresses two consumer needs: temporary relief of minor aches and pains, and nighttime sleep support when sleeplessness is associated with those symptoms.

The product is not a novel chemical entity. Acetaminophen and doxylamine succinate have long-established regulatory histories. The commercial and intellectual-property analysis therefore centers on formulation economics, regulatory compliance, manufacturing reliability, brand ownership, and retail execution.

Product labels can change by manufacturer, contract manufacturer, market, and package size. The current package insert and Drug Facts panel control the applicable inactive-ingredient assessment.

What is the FDA regulatory status of TOPCARE All Night Pain Relief PM?

TOPCARE All Night Pain Relief PM is an OTC drug marketed through established FDA nonprescription drug pathways. The active ingredients fall within long-standing FDA OTC frameworks for analgesic, antipyretic, and nighttime sleep-aid products.

Acetaminophen is regulated under the FDA OTC analgesic, antipyretic, and antirheumatic drug framework. Doxylamine is regulated as an OTC nighttime sleep-aid ingredient. Applicable labeling, warnings, dosage directions, and combination-product requirements must be satisfied under the relevant FDA monographs and regulations, including 21 C.F.R. parts 338 and 343.

Key regulatory constraints include:

• The product must state the acetaminophen and doxylamine strengths accurately.
• The label must include the required warnings for acetaminophen-related liver injury.
• The label must warn against use with other acetaminophen-containing products.
• Doxylamine labeling must address drowsiness, alcohol, sedatives, driving, and other sleep-aid risks.
• The dosage regimen must not encourage use beyond the permitted daily exposure.
• A reformulated product may require updated Drug Facts, stability support, manufacturing documentation, and potentially an FDA filing depending on the change.

Acetaminophen creates a high compliance burden because consumers may unknowingly combine multiple acetaminophen products. FDA has repeatedly highlighted the risk of severe liver injury from excessive acetaminophen exposure.[1]

What excipients are likely used in the product?

Public product labels for store-brand caplets commonly identify excipients from the following functional categories:

Excipient category	Typical materials	Commercial purpose
Diluent	Microcrystalline cellulose, pregelatinized starch	Provides tablet bulk and compressibility
Binder	Povidone, pregelatinized starch	Improves granule or tablet cohesion
Disintegrant	Croscarmellose sodium, sodium starch glycolate	Promotes breakup and dissolution
Lubricant	Magnesium stearate	Reduces sticking and ejection force
Glidant	Colloidal silicon dioxide	Improves powder flow
Coating polymer	Hypromellose, polyethylene glycol	Protects tablet and improves swallowability
Opacifier or pigment	Titanium dioxide or approved colorants	Provides appearance and light protection
Surface treatment	Carnauba wax, talc	Reduces tackiness and improves finish

The exact inactive-ingredient list should be taken from the current product labeling. A change in contract manufacturer can produce a different excipient system without changing the active ingredients or product name.

The principal formulation challenge is the high acetaminophen loading. At 500 mg per unit, the active ingredient represents a substantial portion of tablet mass. Doxylamine succinate adds a lower-dose but pharmacotechnically important component. The formulation must prevent segregation, achieve content uniformity, compress consistently, disintegrate within specification, and remain stable under retail storage conditions.

How should the excipient strategy be designed?

A practical excipient strategy should prioritize manufacturing robustness and consumer use over novelty.

1. Use a direct-compression platform where feasible

A direct-compression formulation can reduce processing steps, solvent use, drying time, and manufacturing cost. Microcrystalline cellulose, spray-dried lactose, mannitol, or directly compressible starch can provide the necessary compactability.

The principal risk is segregation. Acetaminophen has relatively high loading, while doxylamine succinate is present at a much lower concentration. Differences in particle size, density, and flow may cause content-uniformity problems. A robust blend should use:

• Narrow particle-size distributions.
• Controlled order of addition.
• Low-shear blending where appropriate.
• Validated blend-hold times.
• Excipient grades selected for consistent flow and compaction.

If direct compression cannot maintain uniformity, dry granulation is a practical alternative. Roller compaction can improve flow without introducing water, which may be useful for moisture-sensitive components or for controlling tablet density.

2. Optimize disintegration without compromising tablet strength

Nighttime pain products should dissolve promptly after administration. Excessive hardness, hydrophobic lubrication, or an overly dense coating can delay disintegration.

A formulation-development program should evaluate:

• Croscarmellose sodium versus sodium starch glycolate.
• Intragranular and extragranular disintegrant placement.
• Magnesium stearate concentration and blending time.
• Tablet hardness and friability.
• Disintegration and dissolution after accelerated aging.

The objective is not simply the fastest possible dissolution. The target is reproducible dissolution across commercial equipment, scale, humidity exposure, and tablet hardness ranges.

3. Improve swallowability

Caplets containing 500 mg of acetaminophen can be large. A film coat can reduce friction, improve mouthfeel, mask odor, and reduce consumer resistance.

Commercially useful coating options include:

• Hypromellose-based film coating.
• Polyethylene glycol plasticization.
• Low-tack aqueous coating systems.
• Color-free or low-color coatings for a clean-label position.
• Modified caplet geometry with tapered edges.

A smaller tablet may require higher-density excipients or a multilayer design. That can raise manufacturing complexity and compression risk. For a mass-market store brand, a standard coated caplet is usually more economical than a highly engineered dosage form.

4. Manage moisture and packaging interaction

Acetaminophen products can encounter stability issues related to moisture, discoloration, tablet softening, coating defects, and dissolution drift. The selected excipients and packaging system should be assessed together.

Recommended commercial packaging options include:

• High-barrier blister packaging.
• HDPE bottles with induction seals.
• Desiccant-containing bottles where justified.
• Child-resistant closures.
• Unit-dose packaging for travel and institutional channels.

Packaging can deliver more commercial value than a marginal excipient change. Unit-dose blister packs, for example, can support adherence, portability, and pharmacy-channel distribution while reducing handling errors.

5. Consider a differentiated color and “clean-label” profile

A private-label product can gain shelf differentiation through:

• Dye-free tablets.
• Titanium-dioxide-free coating systems where commercially practical.
• Gluten-free positioning when supported by supplier controls.
• Lactose-free positioning.
• Vegan-suitable excipient selection.
• Reduced excipient count.

These claims require substantiation and controlled supply chains. They should not compromise appearance, stability, dissolution, or cost. A clean-label version is more likely to support a premium store-brand tier than a conventional value-tier product.

What formulation patents protect this product?

There is no obvious basis to treat TOPCARE All Night Pain Relief PM as a product protected by a commercially meaningful patent estate. The active ingredients are old, and conventional acetaminophen-doxylamine caplets are generally vulnerable to substitution by other OTC manufacturers.

Potential intellectual-property areas include:

IP area	Potential strength	Commercial relevance
Acetaminophen-doxylamine combination	Low for conventional compositions	Limited protection unless a non-obvious formulation is claimed
Standard tablet excipients	Low	Usually covered by expired, generic, or nonexclusive know-how
Film coating	Low to moderate	Potentially protectable only with a specific technical advantage
Modified-release delivery	Moderate to high if technically novel	Could support differentiation but may change the product profile
Bilayer or multilayer tablet	Moderate	May protect separation or dose control if supported by data
Taste-masking system	Moderate	More relevant to chewable or liquid formats
Packaging configuration	Low to moderate	May support trade dress or design protection
Manufacturing process	Moderate	Can protect yield, uniformity, or stability improvements
Brand and trade dress	Commercially meaningful	Trademark and shelf recognition are more important than patents

For the existing conventional product, freedom to operate is more likely to depend on avoiding third-party patents covering unusual delivery systems, coating compositions, packaging, or manufacturing processes than on defending a core active-ingredient patent.

What is the Orange Book status of TOPCARE All Night Pain Relief PM?

TOPCARE All Night Pain Relief PM is not generally expected to have an Orange Book patent listing comparable to an NDA product with active patent exclusivity. Conventional OTC monograph products usually do not depend on Orange Book-listed patents for market protection.

This has several consequences:

• There is no conventional Paragraph IV strategy directed at the core product in the same way used against a patented prescription drug.
• Generic or private-label competitors can enter through their own compliant OTC products.
• Product substitution is governed primarily by FDA compliance, retailer qualification, supply economics, and branding.
• Any protection is more likely to arise from trademarks, trade dress, confidential manufacturing know-how, or a separately developed formulation.

A manufacturer developing a competing product should still conduct a current patent search for formulation, delivery, packaging, and manufacturing claims. The absence of a core Orange Book patent does not eliminate all freedom-to-operate risk.

When does TOPCARE All Night Pain Relief PM lose exclusivity?

The product has no conventional drug patent exclusivity period comparable to a new prescription medicine. Market exclusivity is effectively based on:

1. Retail placement.
2. Private-label contracting.
3. Cost and service performance.
4. Quality history.
5. Consumer recognition.
6. Manufacturing capacity.
7. Compliance with FDA labeling and quality requirements.

A competitor can enter with a therapeutically equivalent OTC product without waiting for patent expiration if it meets the applicable regulatory requirements. Store-brand exclusivity may still exist contractually between a retailer, Topco or another private-label organization, and a manufacturer. That commercial exclusivity is separate from FDA or patent exclusivity.

What commercial opportunities exist for excipient suppliers?

The largest opportunity is not a patented ingredient. It is a validated, cost-effective excipient platform that improves processing or consumer use.

High-value supplier opportunities

Opportunity	Value proposition	Likely buyer
Direct-compression composite excipient	Fewer process steps and better flow	Contract manufacturer
Low-moisture binder system	Improved stability and reduced drying burden	Tablet manufacturer
Fast-disintegrating excipient blend	Better dissolution at high tablet hardness	Brand owner and manufacturer
Low-friction film coating	Easier swallowing and fewer coating defects	Private-label manufacturer
Dye-free coating	Clean-label positioning	Retailer and brand owner
High-barrier packaging	Improved shelf stability	Retailer and packaging supplier
Low-dust excipient system	Better operator safety and handling	Manufacturing site
Continuous-manufacturing-compatible blend	More consistent throughput	Large-scale manufacturer

A supplier with data showing improved blend uniformity, lower tablet weight variability, shorter cycle times, or reduced coating defects can compete on measurable manufacturing economics. Marketing claims alone are unlikely to support a premium.

Premium-tier line extensions

Potential product extensions include:

• Dye-free nighttime caplets.
• Smaller easy-swallow caplets.
• Unit-dose blister packs.
• Liquid-filled softgels.
• Gelcaps with improved swallowability.
• Chewable or orally disintegrating products, subject to taste-masking requirements.
• Separate daytime and nighttime packages.
• Travel-size packs.
• Senior-oriented packaging with larger print and simplified dosing instructions.

The most commercially realistic extensions are packaging and swallowability improvements. Liquid and chewable formats introduce more significant challenges, including acetaminophen taste, doxylamine bitterness, preservative systems, dose uniformity, and child-safety concerns.

How does TOPCARE compare with competing nighttime analgesics?

Product type	Typical active ingredients	Main differentiation	Excipient opportunity
Acetaminophen-doxylamine PM	Acetaminophen plus doxylamine	Pain relief plus sleep aid	Caplet size, coating, dissolution, packaging
Acetaminophen-diphenhydramine PM	Acetaminophen plus diphenhydramine	Pain relief plus sleep aid	Taste, tablet size, sedation positioning
Ibuprofen-diphenhydramine	NSAID plus diphenhydramine	Pain relief plus sleep aid	Moisture protection, gastric tolerability positioning
Acetaminophen-only nighttime product	Acetaminophen	Pain relief without sedating antihistamine	Packaging and consumer segmentation
Melatonin combination	Analgesic plus melatonin or separate sleep product	Sleep-oriented positioning	Regulatory and claim complexity

TOPCARE’s key competitive advantage is likely price and retailer access. Its vulnerability is low switching cost. Consumers can move between store brands and national brands with limited therapeutic differentiation.

Which companies are challenging the product commercially?

The competitive threat comes from national brands, other private-label retailers, and contract manufacturers able to produce equivalent OTC products. The most relevant competitors include:

• Kenvue’s Tylenol PM portfolio.
• Perrigo private-label and store-brand products.
• Retailer-owned brands sold through pharmacies, supermarkets, and mass merchants.
• Generic OTC manufacturers with acetaminophen-doxylamine combinations.
• E-commerce sellers offering multipacks and value bundles.

Competition is likely to occur through price, package count, retailer promotion, availability, and product ratings rather than patent litigation.

What litigation and Paragraph IV risks affect the product?

No core Paragraph IV litigation risk is expected for a conventional acetaminophen-doxylamine OTC caplet because the active ingredients and basic product concept are longstanding. The more realistic legal risks are:

• Trademark disputes involving “PM,” “All Night,” or similar branding.
• Trade-dress disputes involving tablet color, shape, or packaging.
• False or unsupported clean-label claims.
• Misbranding allegations involving acetaminophen warnings.
• Product-liability claims related to excessive dosing or sedation.
• Contract disputes between retailers and contract manufacturers.
• Patent claims directed to an unusual coating, softgel, modified-release system, or packaging configuration.

A reformulated product should undergo a targeted freedom-to-operate review before launch, particularly if it uses a proprietary softgel, orally disintegrating platform, extended-release profile, or novel blister system.

What manufacturing and IP barriers exist?

The manufacturing barriers are operational rather than molecule-specific:

• Achieving uniform distribution of low-dose doxylamine in a high-load acetaminophen blend.
• Controlling tablet weight and hardness.
• Preventing sticking and picking during compression.
• Maintaining dissolution after coating and aging.
• Managing acetaminophen dust and cross-contamination.
• Validating cleaning procedures.
• Maintaining reliable supply of coating polymers and functional excipients.
• Complying with current good manufacturing practice requirements.

The most defensible know-how may involve blend design, compression parameters, coating conditions, packaging selection, and stability controls. Those advantages can remain confidential and may be more valuable than a narrow patent with limited enforceability.

What revenue exposure and market opportunity exist?

Revenue exposure is concentrated in high-volume, low-margin OTC retail. The product’s economics depend on unit velocity, retailer margin, promotion frequency, and manufacturing scale.

The main commercial levers are:

Lever	Effect on economics
Larger bottle count	Lowers packaging cost per dose and supports value positioning
Blister packaging	Raises cost but supports portability and dose control
Premium coating	Raises unit cost but may support a premium tier
Contract manufacturing scale	Reduces conversion cost
Retailer exclusivity	Improves shelf access but may limit channel expansion
E-commerce multipacks	Increases basket size and reduces per-unit fulfillment cost
Clean-label positioning	Can support a price premium if consumer demand is demonstrated

A conventional product should generally be managed as a scale and availability business. A differentiated excipient or delivery system is commercially attractive only if it produces one of three outcomes: lower cost, lower quality risk, or a credible consumer benefit.

What is the recommended excipient development plan?

A commercially disciplined development plan would use three formulation tiers:

Value formulation

Use a conventional direct-compression or dry-granulation platform with standard disintegrants, magnesium stearate, and an economical film coat. This tier targets retailer cost and manufacturing throughput.

Enhanced swallowability formulation

Use a tapered caplet, lower-friction coating, optimized tablet hardness, and potentially a smaller-dimension platform. This tier targets older consumers and consumers who experience difficulty swallowing large tablets.

Premium clean-label formulation

Evaluate dye-free, lactose-free, and simplified excipient systems with high-barrier packaging. This tier requires substantiated claims and should be tested for consumer willingness to pay.

Development testing should include blend uniformity, tablet mechanical properties, disintegration, dissolution, accelerated stability, photostability where relevant, extractables and leachables for packaging, and transport simulation.

Key Takeaways

• TOPCARE All Night Pain Relief PM is a conventional OTC combination of acetaminophen and doxylamine succinate.
• The product is unlikely to have meaningful core patent or Orange Book protection.
• Commercial exclusivity depends on retailer relationships, private-label contracts, manufacturing scale, and shelf access.
• The strongest excipient opportunities are direct compression, rapid disintegration, low-friction coating, moisture control, and clean-label positioning.
• Doxylamine’s lower dose creates content-uniformity and blend-segregation risks within a high-load acetaminophen tablet.
• Packaging and swallowability improvements are more commercially realistic than complex modified-release systems.
• Paragraph IV litigation is not the principal competitive risk.
• Formulation know-how, process controls, supplier qualification, and retailer execution are the main defensible assets.

FAQs

Can a competitor launch an acetaminophen-doxylamine product without licensing TOPCARE?

Yes. A competitor can generally develop and market its own compliant OTC product without licensing TOPCARE, subject to FDA requirements, trademark clearance, trade-dress review, and freedom-to-operate analysis for any proprietary formulation or packaging technology.

Is doxylamine a better nighttime ingredient than diphenhydramine for a private-label product?

The choice depends on target labeling, consumer positioning, supply economics, and formulation performance. Doxylamine supports a differentiated product profile, but both ingredients create sedation-related warnings and require careful label compliance.

Can an excipient change create a new patent opportunity?

Yes, but the change must provide a non-obvious technical result. Examples could include materially improved content uniformity, stability, dissolution, swallowability, or manufacturing yield. A routine substitution of one conventional filler or disintegrant for another is unlikely to support strong patent protection.

Would an orally disintegrating version create a meaningful commercial advantage?

Potentially, but taste masking would be a central challenge. Acetaminophen and doxylamine must be acceptable in the mouth, and the product would require robust control of dose uniformity, friability, moisture sensitivity, packaging, and child-safety risks.

Is a softgel formulation commercially attractive?

A softgel could improve swallowability and create visual differentiation, but it would raise manufacturing cost and introduce compatibility, fill-weight, shell stability, leakage, and supply-chain considerations. It is more suitable for a premium line than a lowest-cost store-brand product.

References

1. U.S. Food and Drug Administration. (n.d.). Acetaminophen and liver injury: Q&A for consumers. https://www.fda.gov
2. U.S. Food and Drug Administration. (n.d.). DailyMed: TOPCARE All Night Pain Relief PM labeling. National Library of Medicine. https://dailymed.nlm.nih.gov
3. U.S. Food and Drug Administration. (2020). OTC monograph M012: Internal analgesic, antipyretic, and antirheumatic drug products. https://www.fda.gov
4. U.S. Food and Drug Administration. (2020). OTC monograph M013: Nighttime sleep-aid drug products. https://www.fda.gov
5. Electronic Code of Federal Regulations. (n.d.). 21 C.F.R. Part 338: Miscellaneous internal drug products for over-the-counter human use. https://www.ecfr.gov
6. Electronic Code of Federal Regulations. (n.d.). 21 C.F.R. Part 343: Internal analgesic, antipyretic, and antirheumatic drug products for over-the-counter human use. https://www.ecfr.gov